• 2
    Boyle P. Some recent developments in the epidemiology of colorectal cancer. In: BleibergH, RougierP, WilkeHJ, editors. Management of colorectal cancer. London: Martin Dunitz, 1998: 1934.
  • 2
    Harris JR, Adam G. Survival and relapse in adjuvant autologous tumor vaccine therapy for Dukes B and C colon cancer. Proc Am Soc Clin Oncol. 1994; 13: 294.
  • 3
    O'Connell M, Lauie JA, Shepherd L, et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group [abstract]. Proc Am Soc Clin Oncol. 1996; 15: 209.
  • 4
    Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998; 4: 321327.
  • 5
    Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 1998; 4: 328332.
  • 6
    van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254: 16431647.
  • 7
    Gaugler B, Van den Eynde B, van der Bruggen P,et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994; 179: 921930.
  • 8
    Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995; 182: 689698.
  • 9
    Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994; 91: 35153519.
  • 10
    Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 1995; 63: 883885.
  • 11
    Gohara R, Nakao M, Ogata Y, Isomoto H, Oizumi K, Itoh K. Histocompatibility leucocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing in tumor-infiltrating lymphocytes of patients with colon cancer. Jpn J Cancer Res. 1997; 88: 198204.
  • 12
    Naito Y, Saitol K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998 58: 34913494.
  • 13
    Gold P, Freedman SO. Demonstration of tumour specific antigen in human colonic carcinoma by immunologic tolerance and absorption technique. J Exp Med. 1965; 121: 439462.
  • 14
    Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Fuhrer P. Colorectal carcinoma antigen detected by hybridoma antibodies. Somatic Cell Genet. 1979; 5: 957971.
  • 15
    Sasatomi T, Yamana H, Shichijo K, et al. Expression of the SART1 tumor-rejection antigens in colorectal cancers Dis Colon Rectum. 2000; 43: 17541758.
  • 16
    Nakao M, Shichijo S, Imaizumi T, et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol. 2000; 164: 25652574.
  • 17
    Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res. 1999; 59: 40564063.
  • 18
    Kakegawa T, Itoh K. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res. 1995; 55: 42484252.
  • 19
    Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med. 1998; 187: 277288.
  • 20
    Kikuchi M, Nakao M, Inoue Y, et al. Identification of a SART-1-derived peptide capable of inducing the HLA-A24 restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer. 1999; 81: 459466.
  • 21
    Itoh M, Shichijo S, Miyagi Y, et al. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer. 2000; 88: 633639.
  • 22
    Imanishi T, Akazawa T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: TsujiK, AizawaM, SasazukiT, editors. HLA. vol. 1. Oxford: Oxford Scientific Publications 1992: 10651220.